Opendata, web and dolomites

EIS SIGNED

An innovative, effective and minimally-invasive retinal cell therapy combined with a new injection system for treatment of retinal degenerative diseases.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EIS project word cloud

Explore the words cloud of the EIS project. It provides you a very rough idea of what is the project "EIS" about.

first    reduces    market    glaucoma    consequence    multiple    therapeutic    area    fact    ocular    strategy    stromal    amd    pressure    patients    transplantation    platform    safe    injections    retina    innovation    cells    hbm    drug    cell    obtain    bone    clinical    80    perform    degenerative    initiated    mesenchymal    minimally    million    retinal    utilizing    chain    visual    device    approximately    ivts    disease    performed    combination    blood    worldwide    regard    close    causes    mscs    cataract    choroidal    life    standard    impairments    vessels    feasibility    geographic    people    supply    treatment    marketing    iop    photoreceptor    macular    setting    eis    lasting    license    techniques    rp    intravitreal    ga    suffering    billion    age    atrophy    registered    daily    debilitating    risk    degeneration    innovative    pigmentosa    organ    severe    leaving    longer    plan    ensures    dosage    optimal    opportunity    everads    escalation    injection    ivt    effect    treatments    invasive    adult    office    matrix    retinitis    drafted    dr    blindness    excellent    human    trials    subretinal    marrow    goto    treat   

Project "EIS" data sheet

The following table provides information about the project.

Coordinator
EVERADS THERAPY LTD 

Organization address
address: 27 HABARZEL STREET MIGDALEI ORR BUILDING A 5TH FLO
city: TEL AVIV
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EVERADS THERAPY LTD IL (TEL AVIV) coordinator 50˙000.00

Map

 Project objective

Retinal degenerative disease is a debilitating condition with a major impact on daily life. This includes Geographic Atrophy(GA) - as a consequence of age-related macular degeneration (AMD) - and advanced Retinitis Pigmentosa (RP) - all characterized by photoreceptor loss. In fact, they are the main causes of registered blindness. In this regard, there are no currently effective treatments for patients suffering from GA a and RP, leaving approximately 2.6 million people across Europe and over 5 million worldwide with the risk of developing severe visual impairments. Standard techniques to treat GA and DR, including Intravitreal Injections (IVTs) and subretinal transplantation present major problems associated with them. Everads developed a treatment for macular and retinal degeneration, utilizing the innovative Everads Injection System (EIS), a minimally invasive platform for optimal injection of Adult Bone Marrow Mesenchymal Stromal Cells (hBM-MSCs). Unique treatment approach allows simple, office-based safe transplantation of hBM-MSCs in the matrix between the choroidal blood vessels, providing excellent distribution very close to the target organ (retina) and long-term therapeutic effects, targeting multi-billion market opportunity. The Everads treatment is safe, minimally-invasive, can be performed in an office setting and ensures 80% drug distribution in the retinal area, aiming for longer lasting effect of drug. It also reduces the risk of side effects like increased Intra Ocular Pressure (IOP), glaucoma, cataract typical of IVT injections. During the feasibility assessment, a goto market strategy and a supply chain will be established, and further development plan will be drafted. During the phase 2 of innovation project, Everads will perform further product development and cell distribution and dosage escalation activities. Multiple first in human clinical trials will be initiated to obtain marketing license as a drug-device combination product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LiCrete (2018)

LiCrete - Light transmitting composite material for building purposes

Read More